- Home
- MMT vs ACIU Comparison
MMT vs ACIU Comparison
Compare MMT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMT
- ACIU
- Stock Information
- Founded
- MMT 1987
- ACIU 2003
- Country
- MMT United States
- ACIU Switzerland
- Employees
- MMT N/A
- ACIU N/A
- Industry
- MMT Trusts Except Educational Religious and Charitable
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- MMT Finance
- ACIU Health Care
- Exchange
- MMT Nasdaq
- ACIU Nasdaq
- Market Cap
- MMT 270.5M
- ACIU 319.6M
- IPO Year
- MMT N/A
- ACIU 2016
- Fundamental
- Price
- MMT $4.80
- ACIU $3.11
- Analyst Decision
- MMT
- ACIU Strong Buy
- Analyst Count
- MMT 0
- ACIU 2
- Target Price
- MMT N/A
- ACIU $12.00
- AVG Volume (30 Days)
- MMT 86.5K
- ACIU 78.4K
- Earning Date
- MMT 01-01-0001
- ACIU 11-01-2024
- Dividend Yield
- MMT 8.58%
- ACIU N/A
- EPS Growth
- MMT N/A
- ACIU N/A
- EPS
- MMT 0.30
- ACIU N/A
- Revenue
- MMT N/A
- ACIU $17,235,700.00
- Revenue This Year
- MMT N/A
- ACIU N/A
- Revenue Next Year
- MMT N/A
- ACIU $974.52
- P/E Ratio
- MMT $15.33
- ACIU N/A
- Revenue Growth
- MMT N/A
- ACIU 293.60
- 52 Week Low
- MMT $4.04
- ACIU $2.25
- 52 Week High
- MMT $4.70
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- MMT 37.80
- ACIU 36.48
- Support Level
- MMT $4.84
- ACIU $3.17
- Resistance Level
- MMT $4.89
- ACIU $3.37
- Average True Range (ATR)
- MMT 0.03
- ACIU 0.15
- MACD
- MMT -0.01
- ACIU -0.04
- Stochastic Oscillator
- MMT 0.00
- ACIU 17.65
About MMT MFS Multimarket Income Trust
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.